Small is powerful for the pharmaceutical industry

An award winning specialist in nanoparticle engineering technology, Nanoform recently launched a US subsidiary, citing growing demand for its technology from US pharma companies, and extended its partnership with Orion Corporation, a Finnish pharmaceutical company, to apply Nanoform's award-winning CESS® technology to new chemical entities. Christian Jones, Chief Commercial Officer at Nanoform, believes they are now well positioned to continue to expand their reach, with the ambition to provide more drugs with a second chance at reaching the market.

Nanoform's mission is to support the life sciences industry by overcoming drug development and delivery challenges through its multi-patented CESS® technology. This technology enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. A higher rate of dissolution and improved bioavailability also lowers the dosage required for a therapeutic effect, resulting in a reduction in both side effects and wastage of drugs in the body. The latter has a positive impact on the environment, Mr. Jones points out. In addition, Nanoform's green particle engineering process produces pure and stable nanoparticles as small as 10 nm using supercritical carbon dioxide. "There are several bottom-up and top down approaches to improve the rate of dissolution but we believe our bottom-up approach is superior, particularly as we do not use surfactants; the pharmaceutical industry doesn't like surfactants as they may cause side effects for patients," Mr. Jones explains.

Mr. Jones joined the team in October 2018 to help transform the company from technology start-up to commercial entity. Since that time, there have been numerous high-profile appointments to the Nanoform management team. The company secured the appointment of Dr. Gonçalo Rebelo de Andrade as Chief of Business Operations; he has substantial knowledge of particle engineering through his previous role as Business Development Manager for the inhalation business at Hovione, a particle engineering contract development and manufacturing company. "The appointment came at an important time in the company's evolution following considerable investment in our people and facilities," says Mr. Jones. "Dr. Andrade's background and experience in drug delivery is a huge asset to the company and he will play a key role in the international expansion of our business."

To support their plan to work closely with the global pharmaceutical industry in drug development, from the proof of concept stage through to process optimisation and GMP manufacturing, Nanoform has also appointed Dr David Rowe, ex particle size reduction lead for GSK, as Head of Manufacturing for Nanoform and is responsible for implementing and leading the GMP activities at the company.

There was more good news for Nanoform when Finland-based Orion Corporation announced it would use Nanoform's proprietary CESS® technology to enhance the company's formulation process and provide poorly soluble molecules with a path to clinical trials. As a company that covers the entire life-cycle from research and development, to commercial manufacturing and marketing of pharmaceuticals, Orion is continuously developing new drugs and treatment methods.

These moves combined with the establishment of a US subsidiary are all logical steps in the evolution of Nanoform, in Mr. Jones' view, as they are looking to expand the reach of their nanoforming™ technology. "We already have contacts and partners in the US, and we want to be in close proximity to them."

nanoform
small is powerful

Nanoform

Website: www.nanoform.com